Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma

British Journal of Cancer

Volumn 100, Issue 8, 2009, Pages 1257-1266

  Yoshikawa, D ^a,b   Ojima, H ^a   Kokubu, A ^a   Ochiya, T ^a   Kasai, S ^b   Hirohashi, S ^a   Shibata, T ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Cholangiocarcinoma; EGFR; In vivo imaging; Molecular targeted therapy; VEGFR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; VANDETANIB; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; GENE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KRAS GENE; METASTASIS; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL DIVISION; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; JAPAN; MICE; MICE, INBRED BALB C; MICE, NUDE; PIPERIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 64949187144     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604988     Document Type: Article

References (46)

1. SAPK. Cancer Res 63(7): 1684-1695
2. Angelucci A, Gravina GL, Rucci N, Millimaggi D, Festuccia C, Muzi P, Teti A, Vicentini C, Bologna M (2006) Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer 13(1): 197-210
3. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn Jr PA, Varella Garcia M (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97(9): 643-655
4. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G (2004) Anti-tumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10(2): 784-793
5. Ellis LM, Fidler IJ (1996) Angiogenesis and metastasis. Eur J Cancer 32A(14): 2451-2460
6. Fidler IJ, Ellis LM (1994) The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79(2): 185-188
7. Gonzalez Angulo AM, Hortobagyi GN, Esteva FJ (2006) Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11(8): 857-867
8. Gwak GY, Yoon JH, Shin CM, Ahn YJ, Chung JK, Kim YA, Kim TY, Lee HS (2005) Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol 131: 649-652
9. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spasova I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS (2007a) Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25(27): 4270-4277
10. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt W, Herbst RS, Krebs A, Langmuir P, Johnson BE (2007b) Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25No. 18S (June 20 Suppl): 7544
11. Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, Rosenthal MA, Wheeler C, Barge A, Hurwitz HI (2005) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16(8): 1391-1397
12. Jenkins DE, Yu SF, Hornig YS, Purchio T, Contag PR (2003) In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis 20(8): 745-756
13. Jimeno A, Rubio Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P, Sebastiani V, Maitra A, Hidalgo M (2005) Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 65(8): 3003-3010
14. Khan SA, Thomas HC, Davidson BR, Taylor Robinson SD (2005) Cholangiocarcinoma. Lancet 366(9493): 1303-1314
15. Kiguchi K, Ruffino L, Kawamoto T, Ajiki T, Digiovanni J (2005) Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. Clin Cancer Res 11(15): 5572-5580
16. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23(10): 2332-2338
17. Küsters B, Kats G, Roodink I, Verrijp K, Wesseling P, Ruiter DJ, de Waal RMW, Leenders WPJ (2007) Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis. Oncogene 26(39): 5808-5815
18. Leone F, Cavalloni G, Pignochino Y, Sarotto I, Ferraris R, Piacibello W, Venesio T, Capussotti L, Risio M, Aglietta M (2006) Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res 12: 1680-1685
19. Levy AP, Levy NS, Goldberg MA (1996) Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 271(5): 2746-2753
20. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault Llorca F, Laurent Puig P (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66(8): 3992-3995
21. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21): 2129-2139
22. Mezquita P, Parghi SS, Brandvold KA, Ruddell A (2005) Myc regulates VEGF production in B cells by stimulating initiation of VEGF mRNA translation. Oncogene 24(5): 889-901
23. Minakuchi Y, Takeshita F, Kosaka N, Sasaki H, Yamamoto Y, Kouno M, Honma K, Nagahara S, Hanai K, Sano A, Kato T, Terada M, Ochiya T (2004) Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 32(13): e109
24. Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A (2005) Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 206(3): 356-365
25. Natale RB, Bodkin B, Govindan R, Sleckman B, Rizvi N, Capo A, Germonpré P, Stockman P, Kennedy S, Ranson M (2006) ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 24No. 18S (June 20 Suppl): 7000
26. Nogawa M, Yuasa T, Kimura S, Kuroda J, Sato K, Segawa H, Yokota A, Maekawa T (2005) Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett 217(2): 243-253
27. Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, Fujii H, Takeda Y, Dobashi Y (2004) Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 17(8): 895-904
28. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676): 1497-1500
29. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(36): 13306-13311
30. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLo S Med 2(1): e17
31. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C (2006) Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24(19): 3069-3074
32. Sirica AE (2005) Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41: 5-15
33. Tabernero J (2007) The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5(3): 203-220
34. Tada M, Omata M, Ohto M (1990) Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Res 50(4): 1121-1124
35. Taguchi F, Koh Y, Koizumi F, Tamura T, Saijo N, Nishio K (2004) Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ('Iressa')-sensitive and resistant xenograft models. Cancer Sci 95(12): 984-989
36. Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H, Horiike A, Fujisaka Y, Shinkai T, Tahara M, Kawada K, Ebi H, Sasaki Y, Jiang H, Saijo N (2006) A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 1(9): 1002-1009
37. Tang D, Nagano H, Yamamoto H, Wada H, Nakamura M, Kondo M, Ota H, Yoshioka S, Kato H, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Wakasa K, Monden M (2006) Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep 15(3): 525-532
38. INK4A alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 47(5): 721-727
39. Viloria Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61(13): 5090-5101
40. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62(16): 4645-4655
41. Wiedmann M, Feisthammel J, Blüthner T, Tannapfel A, Kamenz T, Kluge A, Mössner J, Caca K (2006) Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and Erb B-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs 17(7): 783-795
42. Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, Wedge SR (2004) ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10(24): 8587-8593
43. Yan Y, Lu Y, Wang M, Vikis H, Yao R, Wang Y, Lubet RA, You M (2006) Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer. Mol Cancer Res 4(12): 971-981
44. Yano S, Muguruma H, Matsumori Y, Goto H, Nakataki E, Edakuni N, Tomimoto H, Kakiuchi S, Yamamoto A, Uehara H, Ryan A, Sone S (2005) Antitumor vascular strategy for controlling experimental meta-static spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice. Clin Cancer Res 11(24): 8789-8798
45. Yarden Y, Sliwkowski MX (2001) Untangling the Erb B signalling network. Nat Rev Mol Cell Biol 2(2): 127-137
46. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S, Shibata T (2008) Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98(2): 418-425